You are here: » News » Newsdetails:

News in Detail

Phase I Trial for RGX-314 for Wet AMD Doses Fourth Cohort

Clinical-stage biotechnology company REGENXBIO Inc. announced earlier this month that it has completed dosing of the fourth cohort of six patients in a Phase I clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD or nAMD).